Category: Cystic Fibrosis

AMRI (NASDAQ: AMRI) and the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced a four-year research collaboration, worth up to $23.7 million, aimed at identifying novel treatments that address the core defect in cystic fibrosis.

An international medical meeting will draw more than 3,000 cystic fibrosis experts from all fields of science and medicine to Anaheim Oct. 3 - 6, 2007 to present the latest information and advances in cystic fibrosis drug research and care. The 21st annual North American Cystic Fibrosis Conference is an annual ritual for leading CF research scientists and clinicians to collaborate in an open and noncompetitive environment.

By better understanding how antimicrobials bind and thereby get inactivated in the mucus of air passages, researchers at the University of Illinois may have found a way to help cystic fibrosis patients fight off deadly infections.”While not a cure, this work has potential as a therapeutic strategy against bacterial infections in cystic fibrosis,” said Gerard Wong a professor of materials science and engineering, of physics, and of bioengineering at the U. of I.

The results of a clinical trial, published in late August in the Journal of Pediatrics, indicates that, when used as part of routine therapy, high-dose ibuprofen is safe, and effective in slowing down lung disease in children with cystic fibrosis (CF).Headed by Dr.

Gilead Sciences, Inc., one of the world’s largest biopharmaceutical companies, and Parion Sciences, Inc., a development-stage pharmaceutical company, announced they will co-develop Parion 680, a compound that could become an important new drug in treating the basic defect in cystic fibrosis. This product was identified as part of a $1.7 million award to Parion from Cystic Fibrosis Foundation Therapeutics, Inc.-the CF Foundation’s nonprofit drug discovery and development affiliate.

FoldRx Pharmaceuticals, Inc. (FoldRx) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced that FoldRx will receive up to 22 million dollars over five years to discover and develop new compounds aimed at treating a core defect in cystic fibrosis.

This week, more than 2,500 Cystic Fibrosis Foundation supporters asked Congress to expand health coverage for children with cystic fibrosis. CF volunteers wrote their elected officials to convey the importance of the State Children’s Health Insurance Program (SCHIP), which ensures that many children with cystic fibrosis have access to the health care and treatments that they need. Congress is considering reauthorization of the program.

Mortality rates from pulmonary fibrosis (PF) have increased significantly in recent years, and are predicted to continue to rise, according to researchers from the University of Colorado. Between 1992 and 2003, the age-adjusted mortality rate from PF-an often fatal disease which involves scarring of the lung-rose by nearly 28.4 percent in men, and 41.3 percent in women.

Mpex Pharmaceuticals, Inc. today announced the initiation of a Phase 1b clinical trial with its lead compound, MP-376, in patients with cystic fibrosis (CF). MP-376 is a proprietary aerosolized formulation of the antibiotic levofloxacin that is being developed for the treatment of chronic lung infections due to Pseudomonas aeruginosa in CF patients.

The structure of a novel protein in the bacterium that is the most persistent pathogen in cystic fibrosis (CF) patients has been solved.Hauptman-Woodward Institute scientists Dr. Andrew Gulick, Eric Drake and Dr.